IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
Phase I Study of Convection Enhanced Delivery (CED) of IL13-PE38QQR Infusion After Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma
調査の概要
状態
詳細な説明
This is a Phase I clinical trial of experimental drug IL13-PE38QQR (Study Drug) in patients with newly diagnosed malignant glioma. IL13-PE38QQR is a tumor-targeting agent administered by a continuous infusion directly into the brain around the cavity where the tumor has been removed. Through previous research, this Study Drug has shown potential to control some of the recurrent malignant gliomas, such as glioblastoma multiforme (GBM), anaplastic astrocytoma, and malignant mixed oligoastrocytoma.
The Study Drug is made by combining a human protein (IL13) with a portion of a bacterial toxin protein, Pseudomonas Exotoxin (PE). The IL13 portion binds to receptors on the tumor like a "key to a lock," allowing the PE portion to enter and kill those cells. Since tumor cells preferentially bind the drug, normal (healthy) brain cells are much less likely to be damaged by the drug.
The Study Drug is delivered through tubing or catheters placed directly into the area surrounding the resection cavity. These catheters will be surgically placed within 14 days after the tumor has been removed. A pump is then used to slowly push the drug solution through the catheters using convection-enhanced delivery (CED) over a period of 4 days.
Following treatment with IL13-PE38QQR, all patients will receive standard courses of radiation therapy. In addition, some patients will receive adjuvant temozolomide with radiation therapy and continue with temozolomide after radiation therapy is completed.
Temozolomide is an anti-cancer drug that is approved by the U.S. Food and Drug Administration (FDA) and sold for the treatment of recurrent GBM.
This study will determine the maximum tolerated dose of IL13-PE38QQR when administered by CED after tumor resection and prior to radiation therapy with or without adjuvant temozolomide. Patients with newly diagnosed malignant glioma who have had a gross total resection of their tumor and who meet all other specified eligibility criteria may be entered into the study.
Patients will be divided into 2 groups:
- Stratum A - will receive treatment with IL13-PE38QQR followed by radiation therapy and
- Stratum B - will receive treatment with IL13-PE38QQR followed by radiation therapy with adjuvant temozolomide. Treatment with temozolomide for Stratum B will continue after radiation therapy is completed.
Subgroups (cohorts) of patients will be treated with up to 3 doses of IL13-PE38QQR. Cohorts of 3-6 patients will be treated at each dose level. Enrollment into each subsequent cohort will be dependent upon the safety and tolerability of treatment in the previous cohort.
All patients will need to have histopathological confirmation of malignant glioma diagnosis from tissue sample obtained at the time of gross total resection within 14 days of stereotactic catheter placement. Each patient will have 2-4 standard microinfusion catheters placed and infusion of IL13-PE38QQR will begin within 24 hours of catheter placement. The infusion will last for 96 hours. Approximately 2 weeks after completion of infusion, imaging for radiation therapy planning, a physical examination, and neurological and laboratory assessments will be performed. Patients, if stable, will then receive standard fractionated external beam radiation therapy with a total dose between 5940-6100 cGy using 180 to 200 cGy per fraction.
For those patients assigned to receive temozolomide in combination with radiation therapy, the dose of temozolomide will be administered on each day of radiation therapy and will be based on the patient's body surface area BSA at a dose of 75 mg/m²/day. After radiation therapy is completed and the follow-up MRI has revealed stable disease or a response, patients will continue temozolomide using repeat scheduled dosing at 150 -200 mg/m²/day for 5 consecutive days per 28 day cycle. Treatment cycles will continue for up to 12 cycles.
研究の種類
入学
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
San Francisco、California、アメリカ、94143
- University of California San Francisco - Dept. of Neurological Surgery
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28204
- Carolina Neurosurgery & Spine Assoc.
-
Durham、North Carolina、アメリカ、27710
- Duke University Medical Center
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Foundation Department of Neurological Surgery
-
-
Texas
-
Houston、Texas、アメリカ、77030
- University of Texas M.D. Anderson Cancer Center
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- University of Virginia Health Systems - Department of Neurological Surgery
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients must be ≥18 years old.
- Patients must have undergone a gross total resection of the solid contrast-enhancing lesion(s) > 1.0 cm in diameter.
- Patients must be able to have catheters placed within 14 days of tumor resection (including a planned Gross Total Resection following an initial biopsy or subtotal resection)
- Patients must have histopathologic confirmation of malignant glioma from resection specimen. Diagnosis must be consistent with either GBM, AA, or malignant mixed OA.
- Patients must be in adequate general condition and meet the following criteria:
- a. Karnofsky Performance Scale score ≥ 70
b. Adequate hematologic status:
- Absolute neutrophil count ≥ 1,500/mm³
- Hemoglobin ≥ 10 gm/dL
- Platelets ≥ 100,000/mm³
- PT & aPTT within institutional limits of normal
- Female patients must not be pregnant or breast-feeding.
- Patients must practice an effective method of birth control during the study and for 60 days beyond the last day of infusion.
- Patients must understand the investigational nature of this study and its potential risks and benefits, and sign an approved written informed consent prior to performance of any study-specific procedure.
Exclusion Criteria:
- Patients with residual contrast-enhancing tumor crossing the midline, multifocal tumor not amenable to gross total resection or non-parenchymal tumor dissemination (e.g., subependymal or leptomeningeal).
- Patients with clinically significant increased ICP (e.g., impending herniation), uncontrolled seizures or requirement for immediate palliative treatment.
- Patients who have received any prior anti-tumor treatment (other than corticosteroids) including any investigational agents.
- Patients with any metallic prosthesis that would prevent MRI and/or MRS scanning procedures of the brain.
- Patients unwilling or unable to follow protocol requirements.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
IL13-PE38QQRの臨床試験
-
National Institute of Neurological Disorders and...終了しました
-
INSYS Therapeutics IncPediatric Brain Tumor Consortium (PBTC), St. Jude Children's Research Hospital引きこもった
-
INSYS Therapeutics Inc完了
-
INSYS Therapeutics Inc完了
-
INSYS Therapeutics Inc完了多形性膠芽腫 | 悪性神経膠腫 | 退形成性星細胞腫 | 混合性乏星細胞腫 | 悪性星細胞腫アメリカ
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)引きこもった脳および中枢神経系腫瘍
-
INSYS Therapeutics Inc完了多形性膠芽腫 | 悪性神経膠腫 | 退形成性星細胞腫 | 未分化乏突起膠腫 | 混合性乏星細胞腫アメリカ
-
INSYS Therapeutics Inc完了多形性膠芽腫アメリカ, カナダ, イギリス, ドイツ, イスラエル, オランダ
-
City of Hope Medical CenterNational Cancer Institute (NCI)募集